Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.

Yang Y, Meng YL, Duan SM, Zhan SB, Guan RL, Yue TF, Kong LH, Zhou L, Deng LH, Huang C, Wang S, Wang GY, Wu DF, Zhang CF, Chen F.

Int J Cancer. 2019 Nov 15;145(10):2712-2719. doi: 10.1002/ijc.32344. Epub 2019 Apr 29.

PMID:
30989655
2.
3.

Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma.

Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP.

Cancer. 1998 Dec 1;83(11):2346-52.

PMID:
9840534
4.

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.

5.

Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.

Rezhake R, Hu SY, Zhao S, Xu XQ, Zhao XL, Zhang L, Wang Y, Zhang X, Pan QJ, Qiao YL, Zhao FH.

Int J Cancer. 2019 Jan 1;144(1):34-42. doi: 10.1002/ijc.31633. Epub 2018 Oct 26.

PMID:
29943809
6.

Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker.

Fontecha N, Basaras M, Hernáez S, Andía D, Cisterna R.

BMC Cancer. 2016 Nov 5;16(1):852.

7.

High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway.

Wallace NA, Khanal S, Robinson KL, Wendel SO, Messer JJ, Galloway DA.

J Virol. 2017 Sep 27;91(20). pii: e01084-17. doi: 10.1128/JVI.01084-17. Print 2017 Oct 15.

8.

Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization.

Zhang L, Yang B, Zhang A, Zhou A, Yuan J, Wang Y, Sun L, Cao H, Wang J, Zheng W.

J Med Virol. 2016 Nov;88(11):1982-8. doi: 10.1002/jmv.24541. Epub 2016 Jun 2.

PMID:
27038009
9.

Establishment and Application of a Method for High-Risk Human Papillomavirus Genotyping in Cervical Cancer Tissue.

Zou R, Xie W, Wang H, Wang J, Xiao L, Ji S, Chen X, Zhang L, Xue X, Chen J.

Clin Lab. 2016;62(6):1075-85.

PMID:
27468570
10.

Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women.

Yao YL, Tian QF, Cheng B, Cheng YF, Ye J, Lu WG.

J Zhejiang Univ Sci B. 2017 Mar.;18(3):256-262. doi: 10.1631/jzus.B1600288.

11.

Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.

Han L, Husaiyin S, Zhao F, Rezhake R, Niyazi M.

Clin Lab. 2018 Sep 1;64(9):1363-1371. doi: 10.7754/Clin.Lab.2018.180138.

PMID:
30274003
13.
14.

Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.

Nishida H, Matsumoto Y, Kawana K, Christie RJ, Naito M, Kim BS, Toh K, Min HS, Yi Y, Matsumoto Y, Kim HJ, Miyata K, Taguchi A, Tomio K, Yamashita A, Inoue T, Nakamura H, Fujimoto A, Sato M, Yoshida M, Adachi K, Arimoto T, Wada-Hiraike O, Oda K, Nagamatsu T, Nishiyama N, Kataoka K, Osuga Y, Fujii T.

J Control Release. 2016 Jun 10;231:29-37. doi: 10.1016/j.jconrel.2016.03.016. Epub 2016 Mar 12.

PMID:
26979870
15.

Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings.

Tezcan S, Ozgur D, Ulger M, Aslan G, Gurses I, Serin MS, Giray BG, Dilek S, Emekdas G.

Asian Pac J Cancer Prev. 2014;15(9):3997-4003.

16.

Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.

Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, Chen G, Zheng XW, Zhang LL, Wang HB.

J Virol Methods. 2014 Feb;196:120-5. doi: 10.1016/j.jviromet.2013.10.032. Epub 2013 Nov 9.

PMID:
24216236
17.

Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.

Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR.

J Virol. 2014 Oct;88(20):11965-72. doi: 10.1128/JVI.01879-14. Epub 2014 Aug 6.

18.

Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.

Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, Zhang C, Wang L, Ji T, Li K, He D, Xia X, Liu D, Zhou J, Ma D, Wang H.

Clin Cancer Res. 2014 Dec 15;20(24):6495-503. doi: 10.1158/1078-0432.CCR-14-0250. Epub 2014 Oct 21.

19.

TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.

Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, He D, Xia X, Zhu T, Wei J, Wu P, Wang C, Xi L, Gao Q, Chen G, Liu R, Li K, Li S, Wang S, Zhou J, Ma D, Wang H.

J Clin Invest. 2015 Jan;125(1):425-36. doi: 10.1172/JCI78206. Epub 2014 Dec 15.

20.

Supplemental Content

Support Center